The Impact of Ocular Adverse Effects in Patients Treate Analogs: Changes in Prescription Patterns and Patient F

Journal of Ocular Pharmacology and Therapeutics

25, 145-152

DOI: 10.1089/jop.2008.0072

Citation Report

#	Article	IF	Citations
1	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	1.0	1
2	Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety, 2009, 18, i.	1.9	0
3	Intraocular Pressure and Conjunctival Hyperaemia with Bimatoprost Every 48 Hours Versus Every 24 Hours. Journal of Optometry, 2009, 2, 134-137.	1.3	0
4	Bimatoprost. Drugs and Aging, 2009, 26, 1049-1071.	2.7	20
5	Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 2010, 29, 312-334.	15.5	787
6	Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmology, 2010, 10, 10.	1.4	7
7	Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study. BMC Ophthalmology, 2010, 10, 21.	1.4	15
8	First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmology, 2010, 10, 4.	1.4	16
9	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology, 2010, 4, 741.	1.8	48
10	Patient persistence with first-line antiglaucomatous monotherapy. Clinical Ophthalmology, 2010, 4, 261.	1.8	16
11	Physiciansâ€™ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma. Current Medical Research and Opinion, 2010, 26, 957-963.	1.9	12
12	Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Toxicology in Vitro, 2010, 24, 1324-1331.	2.4	15
13	Use of Glaucoma Medications: State of the Science and Directions for Observational Research. American Journal of Ophthalmology, 2010, 150, 569-574.e9.	3.3	23
14	Hyperemia Reduction After Administration of a Fixed Combination of Bimatoprost and Timolol Maleate to Patients on Prostaglandin or Prostamide Monotherapy. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 611-615.	1.4	9
18	Balancing efficacy and tolerability of prostaglandin analogues and prostaglandinâ€“timolol fixed combinations in primary open-angle glaucoma. Current Medical Research and Opinion, 2011, 27, 1949-1958.	1.9	29
19	Drops, Drops, and More Drops. , 0, , .		2
20	A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. BMC Ophthalmology, 2011, 11, 13.	1.4	2
21	Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Preference and Adherence, 2011, 5, 441.	1.8	127

#	Article	IF	Citations
22	The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: An analysis of efficacy and safety. International Journal of Trichology, 2011, 3, 84.	0.5	24
23	Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network. European Journal of Ophthalmology, 2012, 22, 376-387.	1.3	1
24	Ocular Drug Delivery for Glaucoma Management. Pharmaceutics, 2012, 4, 197-211.	4.5	54
25	Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. Clinical Ophthalmology, 2012, 6, 739.	1.8	15
26	Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Current Medical Research and Opinion, 2013, 29, 1201-1209.	1.9	12
27	Therapeutic uses of prostaglandin F2Î± analogues in ocular disease and novel synthetic strategies. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 109-121.	1.9	27
28	Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clinical Ophthalmology, 2013, 7, 901.	1.8	12
29	Prevalence and Risk Factors for Ocular Surface Disease among Patients Treated over the Long Term for Glaucoma or Ocular Hypertension. European Journal of Ophthalmology, 2013, 23, 47-54.	1.3	79
30	Latanoprost in the treatment of glaucoma. Clinical Ophthalmology, 2014, 8, 1967.	1.8	70
31	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clinical Ophthalmology, 2014, 8, 2541.	1.8	15
32	Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clinical Ophthalmology, 2014, 8, 927.	1.8	13
33	An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial. Clinical Ophthalmology, 2014, 8, 1031.	1.8	11
34	In vivo confocal microscopy of conjunctiva in preservativeâ€free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmologica, 2014, 92, e133-40.	1.1	35
35	24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost. Advances in Therapy, 2014, 31, 592-603.	2.9	19
36	Unilateral Prostaglandin-Associated Periorbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2015, 31, 373-378.	0.8	36
37	Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications. Chinese Medical Journal, 2015, 128, 2444-2449.	2.3	19
38	Patient satisfaction with glaucoma therapy: reality or myth?. Clinical Ophthalmology, 2015, 9, 785.	1.8	57
39	A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. , 2015, 56, 7963.		18

#	Article	IF	Citations
40	New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 203-214.	4.3	52
41	Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clinical Ophthalmology, 2016, Volume 10, 2085-2091.	1.8	13
42	Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. Expert Opinion on Emerging Drugs, 2016, 21, 117-128.	2.4	7
43	Big data and ophthalmic research. Survey of Ophthalmology, 2016, 61, 443-465.	4.0	45
44	Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. Advances in Therapy, 2017, 34, 1411-1425.	2.9	12
45	24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. Advances in Therapy, 2017, 34, 221-235.	2.9	25
46	New classes of glaucoma medications. Current Opinion in Ophthalmology, 2017, 28, 161-168.	2.9	28
47	New pharmacotherapy for the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1939-1946.	1.8	17
48	Areas and factors associated with patients’ dissatisfaction with glaucoma care. Clinical Ophthalmology, 2017, Volume 11, 1849-1857.	1.8	4
49	The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study. Clinical Ophthalmology, 2017, Volume 11, 1175-1181.	1.8	3
50	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs, 2018, 78, 39-64.	10.9	43
51	Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases. Journal of Glaucoma, 2018, 27, 1105-1111.	1.6	25
52	Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naÃ¯ve patients and patients intolerant to other hypotensive medications. Journal Francais D'Ophtalmologie, 2018, 41, 945-954.	0.4	16
53	Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clinical Ophthalmology, 2018, Volume 12, 2399-2407.	1.8	25
54	The use of preservatives in dry eye drops . Clinical Ophthalmology, 2019, Volume 13, 1409-1425.	1.8	58
55	Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1001-1010.	0.9	6
56	Latanoprost, a balanced prostaglandin. Expert Review of Ophthalmology, 2019, 14, 61-72.	0.6	1
57	Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. European Journal of Ophthalmology, 2019, 29, 645-653.	1.3	18

#	Article	IF	Citations
58	White Sclera Painted Contact Lens for Masking of Conjunctival Neovascularization and Hyperemia Following Cosmetic Eye Whitening Procedure. Eye and Contact Lens, 2020, 46, e24-e26.	1.6	1
59	Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments . Clinical Ophthalmology, 2020, Volume 14, 3675-3680.	1.8	17
60	Phase 3, Randomized, 20-Month Study ofÂBimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology, 2020, 127, 1627-1641.	5.2	62
61	Influence of Cost of Care and Adherence in Glaucoma Management: An Update. Journal of Ophthalmology, 2020, 2020, 1-5.	1.3	11
62	New considerations for the clinical efficacy of old and new topical glaucoma medications. Australasian journal of optometry, The, 2021, 104, 350-366.	1.3	7
63	Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma. Journal of Korean Ophthalmological Society, 2021, 62, 531-537.	0.2	0
64	Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial. Scientific Reports, 2021, 11, 14971.	3.3	6
65	Improving Adherence to Topical Medication in Patients with Glaucoma. Patient Preference and Adherence, 2021, Volume 15, 1477-1489.	1.8	21
66	Conjunctivitis: A Systematic Review. Journal of Ophthalmic and Vision Research, 2020, 15, 372-395.	1.0	30
67	Pressure Lowering Medications. , 0, , .		0
68	Tolerancia y Efectividad de los AnÃ¡logos de Prostaglandinas en Pacientes Glaucomatosos. Highlights of Ophthalmology, 2013, 41, 22-26.	0.0	0
69	Tolerance and Effectivity of Prostaglandin Analogues in Glaucoma Patients. Highlights of Ophthalmology, 2013, 41, 19-22.	0.0	0
71	Taflotan, the first preservative-free prostaglandin F2Î± analogue: treatment advantages in primary open-angle glaucoma patients. Ophthalmology Journal, 2016, 9, 59-68.	0.2	1
72	Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). Drugs, 2021, 81, 2017-2033.	10.9	25
73	Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy â€“ A Better Approach?. European Ophthalmic Review, 2020, 14, 21.	0.3	0
74	Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24ÂMonths. Advances in Therapy, 2022, 39, 1659-1677.	2.9	11
76	Budget impact analysis of the XENÂ®63 for the treatment of primary openangle glaucoma in Spain. Archivos De La Sociedad Espanola De Oftalmologia, 2022, , .	0.2	0
77	Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?. Journal of Clinical Medicine, 2023, 12, 6732.	2.4	0